From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Loading…
Solventum
SOLV · NYSE · Health Care Technology
SOLV · NYSE · Health Care Technology
Health Care Technology company based in Saint Paul, Minnesota.
In the last 90 days, no insider of Solventum reported an open-market purchase and 0 open-market sales. Members of Congress disclosed 2 trades in its stock. The latest 13F reports cover the quarter ending Jun 30, 2026. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$88.03
Last 12 months
+19.0%
Market value
$15B
S&P 500 +15.8% over the same dates. Prices adjusted for splits and dividends.
Bets against the stock: 4.86M shares sold short (2.9% of shares outstanding), +13.1% vs the previous count, 5.7 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$2.21B
+2.2% vs the same quarter a year earlier
Free cash flow, last 12 months
−$118M
This quarter $144M, a year earlier $59M
Net debt
$4.68B
Debt $5.08B, cash $403M, at Jun 30, 2026
Net income, last 12 months
$1.43B
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 5, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$8.32B
+0.9% vs the year before
Net income, fiscal 2025
$1.56B
As reported in the annual filing
Shares outstanding
170M
As of Jul 31, 2026
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Tommy Tuberville soldHeld by the filer's joint per the disclosure. Disclosed 824 days after the transaction; reported as an official range, not an exact amount.
2 different filers disclosed SOLV within 90 days. Disclosed 116 days after the transaction; reported as an official range, not an exact amount.
Stock since the trade +30.2% · S&P 500 +14.4% · to Oct 5
A board member of Solventum paid $100K out of pocket for Solventum shares. The Solventum shares held grew by 41%.
J. French Hill soldRepublican, Representative, AR district 22 different filers disclosed SOLV within 90 days. Disclosed 23 days after the transaction; reported as an official range, not an exact amount.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
3 approvals or clearances and 0 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Independent Franchise Partners, LLP
Schedule 13G: passive · filed Jan 27, 2026 · 15.4M shares
Vanguard Capital Management
Schedule 13G: passive · filed Apr 30, 2026 · 10.9M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $73.78 on Oct 6, 2025 to $88.03 on Oct 5, 2026 (+19.3%). Disclosed activity in the last 12 months: 1 insider purchase, 0 insider sales, 1 Congress purchase, 1 Congress sale, 1 fund report of opening or adding and 0 fund reports of trimming or selling out (13F, quarter-end snapshots).
Short sale volume: 52.9% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 56.3%. FINRA daily files, to Oct 5, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Top officer leaving
“Zieselman is replacing Mary Wilcox in this role in connection with her previously announced retirement and will report directly to Wayde McMillan, the Company’s Chief Financial Officer.”
8-K on sec.govTop officer leaving
“The Severance Plan includes several changes compared to the Prior Plan, including, but not limited to: • The Severance Plan provides for 12 months of base salary plus prorated incentive compensation following an eligible termination for direct reports of the Chief Executive Officer, provided that currently serving executive officers who are eligible to receive 18 months of base salary remain eligi”
8-K on sec.govTop officer leaving
“On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.”
8-K on sec.govTop officer leaving
“Knight’s appointment, Chris Barry, Executive Vice President and Group President of MedSurg, will depart the Company effective December 31, 2025.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.